Health-related quality of life in Japanese patients with bladder cancer measured by a newly developed Japanese version of the Bladder Cancer Index.

We validated a Japanese version of the Bladder Cancer Index (BCI) as a tool for measuring health-related quality of life (HRQOL) in bladder cancer patients treated with various surgical procedures.

The reliability and validity of the Japanese BCI were examined in 397 Japanese patients with bladder cancer via cross-sectional analysis. The patients simultaneously completed the Short Form (SF)-12, EQ-5D, and the Functional Assessment of Cancer Therapy-General and Bladder (FACT-G and FACT-BL). The differences in BCI subscales among various treatment groups were analyzed.

This study involved 397 patients (301 males and 96 females), with a mean age of 70 years and a median disease duration of 29 months (IQR: 12-66 months). Of these patients, 221 underwent transurethral resection of a bladder tumor, and 176 patients underwent radical cystectomy (ileal conduit: 101 patients, ileal neobladder: 49, and ureterostomy: 26). Cronbach's alpha coefficient was ≥ 0.78 for all subscales, except the bowel bother subscale. Despite moderate correlations being detected between the function and bother score in urinary and bowel domains, the sexual function score was inversely correlated with the sexual bother score (r = - 0.19). A missing value percentage of > 15% was associated with old age (p < 0.05). The mean domain scores differed significantly among distinct clinically relevant treatment groups.

Although revisions are needed to make it easier for elderly patients to comprehend, we confirmed the reliability and validity of the Japanese BCI. The Japanese BCI could be used for cross-cultural assessments of HRQOL in bladder cancer patients.

International journal of clinical oncology. 2020 Aug 24 [Epub ahead of print]

Takahiro Osawa, John T Wei, Takashige Abe, Michitaka Honda, Shuhei Yamada, Jun Furumido, Hiroshi Kikuchi, Ryuji Matsumoto, Kazushi Hirakawa, Yasuyuki Sato, Yoshihiro Sasaki, Toru Harabayashi, Norikata Takada, Keita Minami, Hiroshi Tanaka, Ken Morita, Akira Kashiwagi, Naoto Miyajima, Tomoshige Akino, Sachiyo Murai, Yoichi M Ito, Shunichi Fukuhara, Katsuhiko Ogasawara, Nobuo Shinohara

Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. ., Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA., Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan., Department Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Fukushima, Japan., Department of Urology, Keiyukai Hospital, Sapporo, Japan., Department of Urology, Kushiro Rosai Hospital, Kushiro, Japan., Department of Urology, Hokkaido Cancer Center, Sapporo, Japan., Department of Urology, Sapporo City General Hospital, Sapporo, Japan., Department of Urology, Kushiro City General Hospital, Kushiro, Japan., Department of Urology, Teine Keijinkai Hospital, Sapporo, Japan., Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan., Section of Clinical Epidemiology, Department of Community Medicine, Kyoto University, Kyoto, Japan., Graduate School of Health Sciences, Hokkaido University, Sapporo, Japan.